Healthcare News - Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF), caused by Rickettsia rickettsii, is one of the most severe infectious diseases in the Americas.

The pathogen targets endothelial cells, leading to widespread microvascular damage, fluid leakage, and severe complications such as pneumonitis, myocarditis, kidney injury, and meningoencephalitis.

In advanced cases, RMSF can cause respiratory distress, cardiac abnormalities, coma, and peripheral gangrene, with high mortality rates if left untreated.

Timely diagnosis and immediate antibiotic administration are critical, as mortality can reach 50% within the first eight days of illness.

RMSF is transmitted through various tick species, with Rhipicephalus sanguineus (brown dog tick) playing a significant role in Mexico, while Amblyomma species contribute to transmission in Brazil and North America.

The disease is endemic across Canada, the United States, Mexico, and South America, with an increasing number of urban outbreaks linked to poor sanitation, high tick populations, and free-roaming dogs.

A One Health approach has identified three primary ecological zones for RMSF transmission: sylvatic (wildlife-based), peridomestic (domesticated animal involvement), and urban (densely populated regions).

Control efforts require vector management, improved veterinary care, environmental modifications, and public health initiatives.

The brown dog tick presents a particular challenge due to its resistance to acaricides, necessitating integrated pest management strategies, including the use of isoxazolines and environmental barriers.

RMSF remains a serious public health concern, demanding coordinated intervention.

Preventative strategies - such as early recognition, vector control, sterilization programs, and public awareness - are essential to reducing transmission and improving patient outcomes.

Healthcare professionals must remain vigilant in identifying and managing suspected cases to mitigate the disease’s increasing burden.

For more information access this Medtigo link .

References: Foley J., López-Pérez A.M., Álvarez-Hernández G (2025) A Wolf at The Door: The Ecology, Epidemiology & Emergence of Community & Urban-Level Rocky Mountain Spotted Fever in The Americas. American Journal of Veterinary Research 86(3):368-378. https://doi.org/10.2460/ajvr.24.11.0368 Accessed March 10, 2025

Healthcare News - FDA Approves Needle-Free Epinephrine Alternative for Pediatric Anaphylaxis

The U.S. Food and Drug Administration (FDA) has approved Neffy, an epinephrine nasal spray developed by ARS Pharmaceuticals, for the emergency treatment of Type I allergic reactions, including anaphylaxis, in children aged four years and older (33–66 lbs.).

This approval marks the first significant advancement in pediatric epinephrine delivery in over 30 years.

Epinephrine remains the first-line treatment for anaphylaxis, yet research indicates that delays in administration are common due to apprehension regarding needle-based auto-injectors.

Neffy addresses this barrier to potential use by providing a precise, needle-free delivery system that simplifies emergency intervention.

Clinical trials have demonstrated its pharmacokinetic and pharmacodynamic equivalency to traditional epinephrine injections, with minimal side effects.

Designed for stability, Neffy maintains efficacy for 24 months at room temperature and withstands extreme temperatures, ensuring reliability in diverse conditions.

The device is user-friendly, enabling non-medical personnel, such as teachers and caregivers, to administer life-saving treatment effectively.

The nasal spray will be available in the U.S. starting May 2025, with affordability initiatives, including co-pay savings and patient assistance programs, ensuring broader accessibility.

The approval of Neffy reflects a growing shift toward needle-free epinephrine solutions, improving anaphylaxis management and patient outcomes in both pre-hospital and in-hospital settings.

For more information access the Medtigo link.

Further Reading:

ARS Pharmaceuticals (2025) FDA Approval of Neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms Accessed March 5, 2024